UPDATE 1-Onyx says FDA agrees on blood cancer drug trial design

* Reaches agreement with FDA on Special Protocol Assessment

* Sees carfilzomib combination trial beginning in H1 2010

Feb 2 (Reuters) - Onyx Pharmaceuticals Inc (ONXX.O) said it reached an agreement with the U.S. Food and Drug Administration on the design of the late-stage trial of its blood cancer drug.

The company said the trial was designed to evaluate the efficacy of its drug, carfilzomib, in combination with certain other compounds.

The trial, expected to begin in the first half of 2010, will enroll patients with relapsed multiple myeloma, Onyx said.

Onyx acquired carfilzomib with its purchase of Proteolix Inc.

Shares of the biopharmaceutical company closed at $28.62 Monday on Nasdaq. (Reporting by Anuradha Ramanathan in Bangalore; Editing by Vinu Pilakkott)